Sec Form 4 Filing - Shirvan Mitchell @ Silexion Therapeutics Corp - 2026-06-04

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Shirvan Mitchell 2. Issuer Name and Ticker or Trading Symbol Silexion Therapeutics Corp [ SLXN] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) CSO and CDO (Last) (First) (Middle) C/O SILEXION THERAPEUTICS CORP, 12 ABBA HILLEL ROAD 3. Date of Earliest Transaction (MM/DD/YY) 06/04/2026 (Street) RAMAT GAN5250606 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares ( 1 ) 06/04/2026 A( 2 ) 6,000 A $ 0 8,789 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy Ordinary Shares) ( 3 ) $ 9,077.1 ( 4 ) 08/15/2024 06/07/2032 Ordinary Shares 48 ( 4 ) 48 ( 4 ) D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Shirvan Mitchell C/O SILEXION THERAPEUTICS CORP 12 ABBA HILLEL ROAD RAMAT GAN5250606 CSO and CDO Signatures /s/ Mirit Horenshtein Hadar, Attorney-in-fact 06/08/2026 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The number of ordinary shares, par value $0.135 per share ("ordinary shares"), reported in this Form 4 reflects an adjustment relative to the last Form 4 filed by the Reporting Person on March 30, 2026 due to the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 27,889 ordinary shares, par value $0.0135, beneficially owned by the Reporting Person as reported in that Form 4 to become 2,789 ordinary shares, par value $0.135, prior to the grant reported in this Form 4). ( 2 )The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors. ( 3 )There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. ( 4 )The number of options to purchase ordinary shares, underlying ordinary shares, and the exercise price of those options reported in this row have been adjusted to reflect the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 478 options to purchase 478 ordinary shares, par value $0.0135, at an exercise price of $907.71 per share, beneficially owned by the Reporting Person, as reported in that Form 4, to become 48 options to purchase 48 ordinary shares, par value $0.135, at an exercise price of $9,077.10 per share).

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.